Surgery Partners, Inc. (SGRY)

Surgery Partners, Inc. (SGRY) is a leading healthcare services company that owns and operates a national network of surgical facilities, headquartered in Brentwood, Tennessee. Led by CEO Eric Evans, Surgery Partners’ strategic mission is to "improve the health of our communities by providing personalized, high-quality, and cost-effective surgical care in an outpatient setting." The company holds a dominant industry position as one of the largest independent operators of Ambulatory Surgery Centers (ASCs) and surgical hospitals in the United States. The company’s vision is to be the premier destination for high-acuity surgical procedures outside of the expensive traditional hospital environment. In late 2025, SGRY stock has seen a valuation re-rating after the company successfully rejected private equity buyout offers to focus on its "Independent Scale-Up" strategy, aiming for full-year 2025 revenue between $3.275 billion and $3.30 billion.

The business operations of Surgery Partners are organized into its Surgical Services and Ancillary Services segments, operating over 180 facilities across 33 states. In fiscal 2025, the company reported a record 6.6% increase in quarterly revenue, driven by a 3.4% rise in same-facility surgical cases. A primary growth driver is the "High-Acuity Migration," where complex procedures in orthopedics and cardiology are shifting from hospitals to Surgery Partners’ ASCs. The 2026 strategic roadmap focuses on "De Novo Development," with over a dozen new "focus factory" sites under construction that are specifically designed for total joint and spine procedures. Surgery Partners holds an "Alignment Moat," as its partnership model with over 5,000 physicians ensures high referral rates and operational excellence. With Adjusted EBITDA margins reaching 16.6% in 2025, the company is using its strong cash flow to prune non-core assets and deleverage its balance sheet, making SGRY stock a top-tier "Flight to Quality" play in the healthcare services sector.

Surgery Partners, Inc. (SGRY) is listed on the NASDAQ Global Select Market. Investors tracking SGRY stock often focus on the company’s "Same-Facility Revenue Growth," which has consistently outperformed the industry average. The SGRY stock price is a primary beneficiary of the structural shift toward value-based care and the increasing preference of payers for lower-cost outpatient settings. For those researching SGRY stock, the company’s 2025 financial health, including $203 million in cash and substantial borrowing capacity, provides a clear path for its $300 million active M&A pipeline. As healthcare costs continue to rise, SGRY stock remains a critical infrastructure play on the modernization of American surgery.